Table 1. Patient characteristics.

No	Age	Gender	Diagnosis	Time ofDiagnosis	Chemotherapycourses	LastChemotherapy	Recruitmenttime	Intervaltime	Chemotherapyregimen
1	39	F	NHL IVA	2008-6-26	9	2009-4-7	2009-4-14	8	GEMOX+ENDOSTAR
2	21	M	NHL IVB	2008-9-12	10	2009-5-5	2009-5-19	14	DICE+ ENDOSTAR
3	29	M	HL IVB	1992-6-14	10	2009-6-1	2009-6-26	26	AraC
4	56	M	NHL IVB	2009-2-16	7	2009-6-22	2009-7-10	19	DICE+ ENDOSTAR
5	26	M	NHL IVB	2009-5-4	3	2009-7-8	2009-7-21	14	CAT
6	62	F	MM III	2009-7-9	1	2009-7-19	2009-7-30	12	BTD
7	47	F	NHL IVB	2009-6-23	1	2009-7-30	2009-8-7	9	R-CHOP
8	40	M	NHL IVB	2009-8-11	3	2009-8-11	2009-8-21	11	MTX
9	30	M	NHL IVA	2009-4-17	5	2009-8-28	2009-9-22	26	VALP
10	65	F	NHL IVB	2004-9-16	16	2009-9-9	2009-10-16	37	FC
11	19	F	NHL IVB	2009-7-16	5	2009-10-14	2009-10-28	15	DICE+ ENDOSTAR
12	35	M	NHL	2009-11-4	1	2009-11-4	2009-11-12	9	VDLP
13	27	M	NHL IVB	2009-10-29	1	2009-11-6	2009-11-20	15	VDLP
14	45	M	NHL IVA	2008-2-26	17	2009-11-25	2009-12-7	14	AraC+ATO+Tioprinin
15	45	M	NHL IVA	2008-5-21	9	2009-12-13	2009-12-15	3	GEMOX
16	31	F	NHL IVA	2007-12-26	16	2009-12-14	2009-12-26	13	VDLP
17	57	F	NHL IVB	2009-7-1	5	2009-12-12	2010-1-15	33	RFC
18	59	F	NHL IIIB	1992-4-10	17	2010-1-14	2010-1-26	13	DICE+ ENDOSTAR
19	48	M	NHL IIIB	2009-11-18	3	2010-1-25	2010-2-9	16	EP
20	31	M	NHL IA	2009-12-14	4	2010-3-12	2010-3-23	12	MTX
21	50	F	NHL IVA	2009-8-7	6	2010-1-15	2010-4-16	91	FC
22	15	M	NHL IVA	2010-1-25	1	2010-4-10	2010-4-21	11	BFM-90
23	32	M	NHL IVA	2009-10-12	6	2010-4-19	2010-5-9	20	MTX
24	45	M	NHL IIIB	2007-2-1	9	2010-3-31	2010-5-24	54	R-COP